S19 Novel Developments in Cushings

Program: Symposia
Clinical Session
Thursday, March 5, 2015: 4:30 PM-6:00 PM
Room 20C (San Diego Convention Center)
**This session is eligible for CME credit**

Supported by Corcept Therapeutics Incorporated

Chair:
Lynnette K Nieman, MD, NIH, Bethesda, MD

Disclosures:
LKN: Editor, Up To Date, Clinical Researcher, HRA Pharma.

This session will start by presenting recent novel data on adrenal causes of Cushing's syndrome and then move to address important issues of long term outcomes in children and adults, and conclude with a discussion of therapeutic strategies to cope with the complex and challenging situation of severe Cushing's syndrome.

4:30 PM
Herve Lefebvre, MD, PHD, INSERM U982, Dept of Endo & Metab Diseases, University Hospital of Rouen, Rouen, France
Nothing to Disclose: HL
5:00 PM
Maya Beth Lodish, MD, Program on Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD
Nothing to Disclose: MBL
5:15 PM
Susan M. Webb, MD, PhD, Endocrinology/Medicine Departments, Hospital Sant Pau, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII and Universitat Autňnoma de Barcelona (UAB), Barcelona, Spain
Disclosure: SMW: Ad Hoc Consultant, Novartis Pharmaceuticals, Advisory Group Member, Novartis Pharmaceuticals.
5:30 PM
Ashley B Grossman, Churchill Hospital, Oxford, United Kingdom
Disclosure: ABG: Ad Hoc Consultant, Lecture fees and Advisory Board, Ad Hoc Consultant, Lecture fees and Advisory Board.
See more of: Symposia